No Data
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
Express News | Sirnaomics Ltd - Monin Ung Appointed as Chairlady
Express News | Sirnaomics - Yang Lu to Retire as Chairman , President
The Concept of Innovative Drugs mostly rose, with Shengnuo Pharmaceutical (02257) increasing by 11.56%. Institutions indicate that pharmaceutical innovation is the core driving force of pharmaceutical growth.
Jinwu Finance | Most Innovative Drug Concepts have risen, with Saint Nutra Pharma (02257) up 11.56%, Baiao Saitu (02315) up 9.68%, Geli Pharma (01672) up 7.98%, Lvzhu Bio (02480) up 4.73%, ZAI LAB (09688) up 4.41%, Connaught (02162) up 1.34%, SINO BIOPHARM (01177) up 0.95%, INNOVENT BIO (01801) up 0.69%. Galaxy Securities stated that 1) pharmaceutical innovation is the core driving force of pharmaceutical growth. Innovative drugs have transitioned from Me-too to
Shengnuo Medical-B (02257.HK): Zhonghui Anda has been appointed as the auditor.
On December 13, Gelonghui reported that Shengnuo Medicine-B (02257.HK) announced that the company received a resignation letter dated December 13, 2024, from Deloitte Touche Tohmatsu. Following the recommendation of the Audit Committee, Zhonghui Anda Certified Public Accountants Limited ("Zhonghui Anda") has been appointed as the company's auditor, effective from December 13, 2024, to fill the temporary vacancy left by Deloitte's resignation, to serve until the end of the company's next annual general meeting of shareholders.
Press Release: Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer
